Rhodiola Stress Meta-analysis: What the Evidence Says
Rhodiola Stress Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systemati
Quick Answer
Rhodiola Stress Meta analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence aware guidance rather than medical advice.
Key Takeaways
- 01This page is generated only from sources stored in the Migaku evidence knowledge base.
- 02Current evidence mix: 1 systematic review, 1 narrative review.
- 03Claims should be interpreted with the source type, study design, population, and publication date in mind.
- 04This article is educational and does not replace care from a qualified clinician.
Rhodiola Stress Meta-analysis: What the Evidence Says
Quick Answer
Rhodiola Stress Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.
Key Takeaways
- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 systematic review, 1 narrative review.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.
Evidence Map
| Source | Evidence type | Level | Date | Identifier |
|---|---|---|---|---|
| Efficacy of plant extracts in heart failure patients: a systematic review and network meta-analysis | systematic review | 1 | 2026-06-12 | 10.1186/s12872-026-05793-x |
| Rhodiola rosea , Ginkgo biloba , and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders | narrative review | 3 | 2026-03-12 | 10.3389/fnut.2026.1762061 |
What The Sources Report
- As a severe consequence or end-stage manifestation of various cardiovascular diseases, Heart failure is associated with persistently high mortality and rehospitalization rates. [Tang Tianjiao (2026); evidence level 1]
- Impaired QoL, frequent hospitalizations, suboptimal disease management, population aging, and increasing risk factors are all closely associated with the pathogenesis and progression of heart failure. [Tang Tianjiao (2026); evidence level 1]
- These limitations have catalyzed an increased global focus on nutraceuticals and phytomedicines possessing multimodal biological activities that transcend mere monoamine reuptake inhibition. [Li Xikun (2026); evidence level 3]
- Unlike prior reviews that focus on individual herbs or broadly defined adaptogens, the present review integrates mechanistic, preclinical, and clinical evidence across these three agents to highlight their complementary rather than redundant actions. [Li Xikun (2026); evidence level 3]
How To Read This Evidence
Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.
Practical Interpretation
There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For rhodiola stress meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.
Limits Of This First Pass
This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.
References
- Tang Tianjiao (2026). Efficacy of plant extracts in heart failure patients: a systematic review and network meta-analysis. DOI: 10.1186/s12872-026-05793-x. PMCID: PMC13262503. PMID: 42277690. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13262503/
- Li Xikun (2026). Rhodiola rosea , Ginkgo biloba , and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders. DOI: 10.3389/fnut.2026.1762061. PMCID: PMC13017319. PMID: 41909050. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13017319/
Safety Note
Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.
FAQ
Frequently Asked Questions
Medically reviewed
Last reviewed June 15, 2026 by Migaku Evidence Review
Related content
